Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Cost-benefit Analysis"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
dewey-ones:"330 - Economics"
dewey-ones:"700 - The arts; fine & decorative arts"
Showing
1
-
20
of
29
Search:
'"Cost-benefit Analysis"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
2
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
3
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
4
Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
5
Antibiotic impregnated cement for primary hip or knee arthroplasty : a review of the clinical and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
6
Antibiotic impregnated cement for primary hip or knee arthroplasty : a review of the clinical and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
7
Pharmacoeconomic review report: Upadacitinib (Rinvoq) (AbbVie) : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an ina...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
8
Biologics for early rheumatoid arthritis : review of health economic studies
by
Movik, Espen
Published 2011
Norwegian Knowledge Centre for the Health Services
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
9
Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
10
Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
12
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
14
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
15
Pharmacoeconomic review report: Sarilumab (Kevzara)
Published 2017
CADTH
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
16
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
17
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
18
Sensory rooms for patients with dementia in long-term care : clinical and cost-effectiveness, and guidelines
by
Banerjee, Srabani
,
Ford, Caitlyn
Published 2018
CADTH
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
19
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
Read Now
20
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
Subjects:
“
...
Cost
-
Benefit
Analysis
...
”
1
2
Back
Narrow Search
Remove Filters
Clear Filter
Classification: 330 - Economics
Clear Filter
Classification: 700 - The arts; fine & decorative arts
Year of Publication
From:
To:
Classification
330 - Economics
700 - The arts; fine & decorative arts
610 - Medicine & health
11
333 - Economics of land & energy
7
140 - Specific philosophical schools
6
000 - Computer science, information & general works
5
more ...
363 - Other social problems & services
5
380 - Commerce, communications & transportation
4
600 - Technology
4
620 - Engineering & allied operations
4
320 - Political science
3
551 - Geology, hydrology & meteorology
3
900 - History & geography
3
530 - Physics
2
576 - Genetics & evolution
2
657 - Accounting
2
297 - Islam, Babism & Bahai Faith
1
340 - Law
1
370 - Education
1
580 - Plants (Botany)
1
630 - Agriculture & related technologies
1
720 - Architecture
1
800 - Literature & rhetoric
1
see all ...
less ...
Language
English
29
Collection
National Center for Biotechnology Information
22
Directory of Open Access Books
7
Author
Canadian Agency for Drugs and Technologies in Health
19
CADTH Canadian Drug Expert Committee
6
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
2
Banerjee, Srabani
1
Bonenberg, Agata
1
Bonenberg, Wojciech
1
more ...
Ford, Caitlyn
1
Gómez, Víctor Alonso
1
Hernández-Callejo, Luis
1
Jelinčić, Daniela Angelina
1
Kapliński, Oleg
1
Konstantakopoulou, Foteini
1
Leite, Vicente
1
Lucchini, Marco
1
Movik, Espen
1
Nasjonalt kunnskapssenter for helsetjenesten
1
Nesmachnow, Sergio
1
Nikolaou, Ioannis
1
Rusu, Eugen
1
Santagata, Remo
1
Schnitzer, Hans
1
Tsagarakis, Konstantinos P.
1
Ulgiati, Sergio
1
van Noordwijk, Meine
1
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=dewey-ones%3A%22700+-+The+arts%3B+fine+%26+decorative+arts%22&lookfor=%22Cost-benefit+Analysis%22&type=Subject
Send by Email
×
Loading...